[
    [
        {
            "time": "2023-10-15",
            "original_text": "AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Qulipta",
                    "FDA",
                    "Migraine",
                    "Drug Approval"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Here's How a New Investor Started Her Portfolio With Just 10 Top Stocks",
            "features": {
                "keywords": [
                    "Investor",
                    "Portfolio",
                    "Top Stocks"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's How a New Investor Started Her Portfolio With Just 10 Top Stocks",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 1,
                "Entity_Density": 1,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie",
            "features": {
                "keywords": [
                    "FDA",
                    "CGRP",
                    "Receptor",
                    "Migraine",
                    "AbbVie"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug",
            "features": {
                "keywords": [
                    "Biotech",
                    "AbbVie",
                    "Migraine",
                    "FDA",
                    "Amicus",
                    "Gene Therapy",
                    "Geovax",
                    "Cancer Drug"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Healthcare",
                    "Long-Term",
                    "Investors"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]